Ledraxen (Enoxaparin Sodium)

Ledraxen, a low molecular weight heparin, is used in clinical situations that require inhibition of clot formation.

• Deep vein thrombosis (DVT) prevention: reduces the risk of clot formation in at‑risk surgical or immobilised patients.
• Pulmonary embolism (PE) treatment: helps dissolve existing clots and prevents new emboli.
• Anticoagulation during hemodialysis: maintains circuit patency by limiting clotting during the procedure.

• Enoxaparin sodium binds to antithrombin III, accelerating its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin formation, thereby preventing the development and propagation of venous thrombi while preserving a degree of normal hemostasis.

Adverse reactions may range from mild to severe and should be monitored throughout therapy.

Common Side Effects

• Injection site pain or erythema: localized discomfort at the administration site.
• Bruising or hematoma: minor bleeding under the skin.
• Mild gastrointestinal upset: nausea or dyspepsia.
• Transient elevation of liver enzymes: mild, reversible changes.
• Minor platelet count reduction: mild thrombocytopenia without clinical sequelae.

Serious or Rare Side Effects

• Major bleeding: gastrointestinal, intracranial or surgical site hemorrhage.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet activation.
• Spinal or epidural hematoma: risk after neuraxial procedures.
• Allergic reactions: urticaria, angioedema or anaphylaxis.
• Elevated liver transaminases: significant hepatic injury.
• Disseminated intravascular coagulation (DIC): uncontrolled clotting and bleeding.

Before initiating Ledraxen, clinicians should assess individual risk factors and monitor patients closely.

• Bleeding risk assessment: evaluate history of hemorrhage, active ulcers or recent surgery.
• Renal function monitoring: dose adjustment may be required in severe impairment.
• Concomitant anticoagulant use: avoid combining with other blood thinners unless medically justified.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Storage at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin can interact with several drug classes, altering its anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhage potential.
• Thrombolytic therapy (e.g., alteplase): synergistic effect on clot dissolution.
• Neuraxial anesthesia or spinal puncture: heightened risk of epidural hematoma.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate bleeding.
• Certain antibiotics (e.g., quinolones, macrolides): can affect platelet function.
• ACE inhibitors or diuretics: monitor renal function and electrolytes.
• Selective serotonin reuptake inhibitors (SSRIs): modest increase in bleeding tendency.